Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1301 on June 17, 2021, to initiate phase I clinical trial for the treatment
Following IND approval by the US FDA in Mid-January, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on January
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1201 on December 15, 2020, to initiate phase I clinical trial for the treatment
T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is new capsule form. T-1101 capsule IND application has been approved
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1101 capsule on Nov. 2021, to initiate phase I clinical trial. T-1101: T-1101 acts
T-1101, oral powder for constitution (OPC), from Taivex has completed the phase I trial in Oct, 2019. Total 21 patients have received T-1101 (Tosylate) OPC
Taivex Therapeutics Corp. (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1301 (formerly, DBPR216), a potential anti-cancer
Dr. Lun Kelvin Tsou, associate Investigator of IBPR. Dr, Tsou with his team members had development a noval small molecule drug conjugate, DBPR115, that could
T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate
